Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario

被引：5

作者：

Meyers, Brandon M. ^{[1
]}

Knox, Jennifer J. ^{[2
]}

Cosby, Roxanne ^{[3
]}

Beecroft, J. R. ^{[4
]}

Chan, Kelvin K. W. ^{[5
]}

Coburn, Natalie ^{[5
]}

Feld, Jordan J. ^{[6
]}

Jonker, Derek ^{[7
]}

Mahmud, Aamer ^{[8
]}

Ringash, Jolie ^{[9
,10
]}

机构：

[1] McMaster Univ, Dept Oncol, Juravinski Canc Ctr, Hamilton, ON, Canada

[2] Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] McMaster Univ, Dept Oncol, Program Evidence Based Care, Hamilton, ON, Canada

[4] Mt Sinai Hosp, Dept Med Imaging, Toronto, ON, Canada

[5] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada

[6] Toronto Gen Hosp, Res Inst, Toronto, ON, Canada

[7] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[8] Canc Ctr Southeastern Ontario, Kingston, ON, Canada

[9] Princess Margaret Canc Ctr, Toronto, ON, Canada

[10] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada

来源：

CANADIAN LIVER JOURNAL | 2021年 / 4卷 / 03期

关键词：

hepatocellular carcinoma; non-surgical treatment; systematic review; systemic therapy; tyrosine kinase inhibitor; PHASE-II TRIAL; DOUBLE-BLIND; TRANSARTERIAL CHEMOEMBOLIZATION; PLUS SORAFENIB; OPEN-LABEL; 1ST-LINE THERAPY; 2ND-LINE TREATMENT; MULTICENTER; PLACEBO; HCC;

D O I：

10.3138/canlivj-2020-0039

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

BACKGROUND: Hepatocellular carcinoma (HCC) is a global health problem, accounting for 4.7% of all new cancer cases and 8.2% of all cancer deaths worldwide in 2018. Resection and transplantation are the only modalities that offer a cure for HCC; however, most patients are diagnosed at an advanced stage, precluding these curative treatments. A number of local (ie, ablative therapies) and/or local-regional therapies (ie, chemo-embolization) are used and followed by systemic therapy for advanced or progressive disease. Other treatments are available, but their efficacy compared with these standards is not well known. METHODS: Literature searches (1/2000 to 1/2020 or 1/2005 to 1/2020, depending on the specific systematic review question) were conducted, including MEDLINE, Embase and the Cochrane Database of Systematic Reviews. RESULTS: Over 30,000 articles were identified. In total, 49 studies were included in the systematic review. CONCLUSIONS: There is no evidence to support the addition of sorafenib to any local or regional therapy. First-line systemic therapy options for unresectable or metastatic HCC include sorafenib, lenvatinib, and atezolizumab + bevacizumab. Regorafenib or cabozantinib provide survival benefits when given as second-line treatment.

引用

页码：257 / 274

页数：18

共 56 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2] Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma [J].

Abou-Alfa, G. K. ;

Qin, S. ;

Ryoo, B-Y. ;

Lu, S-N. ;

Yen, C-J. ;

Feng, Y-H. ;

Lim, H. Y. ;

Izzo, F. ;

Colombo, M. ;

Sarker, D. ;

Bolondi, L. ;

Vaccaro, G. ;

Harris, W. P. ;

Chen, Z. ;

Hubner, R. A. ;

Meyer, T. ;

Sun, W. ;

Harding, J. J. ;

Hollywood, E. M. ;

Ma, J. ;

Wan, P. J. ;

Ly, M. ;

Bomalaski, J. ;

Johnston, A. ;

Lin, C-C. ;

Chao, Y. ;

Chen, L-T. .

ANNALS OF ONCOLOGY, 2018, 29 (06) :1402-1408

[3] Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Phase 3 CALGB 80802 Randomized Clinical Trial [J].

Abou-Alfa, Ghassan K. ;

Shi, Qian ;

Knox, Jennifer J. ;

Kaubisch, Andreas ;

Niedzwiecki, Donna ;

Posey, James ;

Tan, Benjamin R., Jr. ;

Kavan, Petr ;

Goel, Rakesh ;

Lammers, Philip E. ;

Bekaii-Saab, Tanios S. ;

Tam, Vincent C. ;

Rajdev, Lakshmi ;

Kelley, Robin K. ;

El Dika, Imane ;

Zemla, Tyler ;

Potaracke, Ryan, I ;

Balletti, Jennifer ;

El-Khoueiry, Anthony B. ;

Harding, James H. ;

Suga, Jennifer M. ;

Schwartz, Lawrence H. ;

Goldberg, Richard M. ;

Bertagnolli, Monica M. ;

Meyerhardt, Jeffrey ;

O'Reilly, Eileen M. ;

Venook, Alan P. .

JAMA ONCOLOGY, 2019, 5 (11) :1582-1588

[4] Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial [J].

Assenat, Eric ;

Pageaux, Georges-Philippe ;

Thezenas, Simon ;

Peron, Jean-Marie ;

Becouarn, Yves ;

Seitz, Jean-Francois ;

Merle, Philippe ;

Blanc, Jean-Frederic ;

Bouche, Olivier ;

Ramdani, Mohamed ;

Poujol, Sylvain ;

de Forges, Helene ;

Ychou, Marc ;

Boige, Valerie .

BRITISH JOURNAL OF CANCER, 2019, 120 (09) :896-902

[5] Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study) [J].

Azim, Hamdy A. ;

Omar, Ashraf ;

Atef, Hesham ;

Zawahry, Heba ;

Shaker, Mohamed K. ;

Abdelmaksoud, A. H. Kamel ;

EzzElarab, Mohamed ;

Abdel-Rahman, Omar ;

Ismail, Mohamed ;

Kassem, Loay ;

Waked, Imam .

JOURNAL OF HEPATOCELLULAR CARCINOMA, 2018, 5 :109-119

[6]

Baldassarre FG., 2014, FOCAL TUMOR ABLATION

[7] Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib and pravastatin vs best supportive care for the palliative treatment of HCC in CHILD B cirrhotic patients [J].

Blanc, J. -F. ;

Khemissa, F. ;

Bronowicki, J. -P. ;

Monterymard, C. ;

Perarnau, J. -M. ;

Bourgeois, V. ;

Obled, S. ;

Abdelghani, M. B. ;

Mabile-Archambeaud, I. ;

Faroux, R. ;

Seitz, J. -F. ;

Locher, C. ;

Senellart, H. ;

Villing, A. -L. ;

Audemar, F. ;

Costentin, C. ;

Delplanque, G. ;

Manfredi, S. ;

Edeline, J. .

JOURNAL OF HEPATOLOGY, 2018, 68 :S195-S195

[8] AGREE II: advancing guideline development, reporting and evaluation in health care [J].

Brouwers, Melissa C. ;

Kho, Michelle E. ;

Browman, George P. ;

Burgers, Jako S. ;

Cluzeau, Francoise ;

Feder, Gene ;

Fervers, Beatrice ;

Graham, Ian D. ;

Grimshaw, Jeremy ;

Hanna, Steven E. ;

Littlejohns, Peter ;

Makarski, Julie ;

Zitzelsberger, Louise .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2010, 182 (18) :E839-E842

[9]

BRUIX J, 2016, ANN ONCOL S, V27, DOI DOI 10.1093/annonc/mdw435.19

[10] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

← 1 2 3 4 5 6 →